Trillium Therapeutics Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trillium Therapeutics stock.
View analyst ratings for Trillium Therapeutics or view top-rated stocks.

Wall Street analysts have given Trillium Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trillium Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Trillium Therapeutics saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 7,870,000 shares, a decline of 45.0% from the June 30th total of 14,320,000 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is currently 5.7 days. Approximately 9.7% of the company's stock are sold short.
View Trillium Therapeutics' Short Interest.

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Trillium Therapeutics.

Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its quarterly earnings data on Friday, May, 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.06.
View Trillium Therapeutics' earnings history.

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 28.1% and is now trading at $6.65.
View which stocks have been most impacted by COVID-19.

7 brokers have issued twelve-month price objectives for Trillium Therapeutics' stock. Their forecasts range from $14.00 to $28.00. On average, they expect Trillium Therapeutics' share price to reach $21.83 in the next twelve months. This suggests a possible upside of 228.3% from the stock's current price.
View analysts' price targets for Trillium Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Trillium Therapeutics include Verve Therapeutics (VERV), PTC Therapeutics (PTCT), Taro Pharmaceutical Industries (TARO), Pacira BioSciences (PCRX), Prestige Consumer Healthcare (PBH), Sage Therapeutics (SAGE), Insmed (INSM), IGM Biosciences (IGMS), OPKO Health (OPK), Amicus Therapeutics (FOLD), ATA (ATAI), Rocket Pharmaceuticals (RCKT), ALX Oncology (ALXO), Corcept Therapeutics (CORT) and Arcus Biosciences (RCUS).
View all of TRIL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRIL stock can currently be purchased for approximately $6.65.

Trillium Therapeutics has a market capitalization of $696.71 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-59,350,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

Trillium Therapeutics employs 33 workers across the globe.

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Trillium Therapeutics is headquartered at 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9.

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at (416) 595-0627 or via email at [email protected]